logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Alex Chehrazi-Raffle

city of hope comprehensive cancer center
H指数:16
被引数:2,496

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

57 Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

57 TiNivo-2 III期试验的最终分析：替沃扎尼（Tivo）在转移性肾细胞癌（mRCC）患者中的长期结局

Oncologist
IF4.2
2026-09-020
OAAI
Robert Motzer; Bradley McGregor; Laurence Albiges; Javier Molina-Cerrillo; Phillipe Barthelemy; Maria Bourlon; Benjamin Garmezy; Sheik Emambux; Arnab Basu; Raffaele Ratta; Pedro Barata; Jeffrey Yorio; Helen Moon; Alex Chehrazi-Raffle; Roberto Iacovelli; Ralph Hauke; Rana McKay; Kathryn Beckermann; Moshe Ornstein; Toni Choueiri
IUC26666-91 Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC)

IUC26666-91 基于血液学指标预测接受一线免疫检查点抑制剂（ICI）治疗的转移性肾细胞癌（mRCC）患者免疫相关不良事件（irAEs）

Oncologist
IF4.2
2026-08-210
OAAI
R Winayak; X Li; N J Salgia; K Makins; V A De Goes; A Moradi; J Hsu; H Ebrahimi; A Chehrazi-Raffle; S K Pal
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)
FUTURE ONCOLOGY
IF2.6
2025-11-010
PRE
Morgans, Alicia K.; Chehrazi-Raffle, Alex; Niazi, Tamim; Shore, Neal D.; Ross, Ashley E.; Roder, Andreas; Gomes, Andrea Juliana; Supiot, Stephane; Barthelemy, Philippe; Hatano, Koji; Ruiz, Carmen Belen Congregado; Yoshida, Soichiro; Herrera-Imbroda, Bernardo; Gratton, Matthieu; Gschwend, Jurgen E.; Hope, Thomas A.; Joensuu, Heikki; Kuss, Iris; Le Berre, Marie-Aude; Dimova-Dobreva, Miryana; Fizazi, Karim
Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials

真实世界证据表明，在乳头状肾细胞癌中，当代一线策略并未显示出生存优势：呼吁开展随机试验

ONCOLOGIST
IF4.2
2025-10-010
OA
Zugman, Miguel; Rider, Jennifer R.; Dizman, Nazli; Jaime-Casas, Salvador; Goes, Vitor Abreu; Shah, Koral; Castro, Daniela, V; Mercier, Benjamin; Zang, Peter; Ebrahimi, Hedyeh; Barragan-Carrillo, Regina; Sahu, Diwyanshu; Mandora, Prithviraj Vikramsinh; Hsu, Joann; Yip, Wesley; Nguyen, Charles B.; Chehrazi-Raffle, Alex; Miller, Robert; Powles, Thomas; Choueiri, Toni; Pal, Sumanta K.
Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)

拉美裔族裔对肠道微生物组和接受CBM588治疗的免疫检查点抑制剂（ICI）反应的影响，在转移性肾细胞癌（mRCC）患者（pts）中的研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Barragan-Carrillo, R.; Zengin, Z. B.; Dizman, N.; Ebrahimi, H.; Meza, L. A.; Jaime-Casas, S.; Li, X.; Dorff, T. B.; Hsu, J.; Salgia, N.; Chehrazi-Raffle, A.; Tripathi, A.; Castro, D.; Mercier, B.; Caporaso, G.; Lee, K.; Pal, S. K.
Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)

真实世界（RW）中接受辅助纳武利尤单抗（NIVO）治疗，联合或不联合新辅助化疗（NAC）的肌肉浸润性尿路上皮癌（MIUC）患者的特征与结局

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Ebrahimi, H.; Barragan-Carrillo, R.; John, W. S.; Lucht, S.; Miller, T.; Pathak, P.; Bland, E.; Gordon, S.; Laney, J.; Klink, A. J.; Feinberg, B. A.; Singh, N.; Alonso, C.; Patel, M.; Rosenblatt, L. C.; Yin, X.; Chehrazi-Raffle, A.
Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)

多中心分析非精原细胞瘤生殖细胞肿瘤（NSGCTs）患者（pts）接受大剂量化疗（HDCT）后的一线（1L）方案（BEP vs VIP）的比较。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Ebrahimi, H.; Shodiya, M.; Maldonado, E.; Othman, T.; Barragan-Carrillo, R.; Li, X.; Rock, A.; Tripathi, A.; Pal, S. K.; Dorff, T. B.; Zhumkhawala, A.; Hoeg, R. Tetens; Oliai, C.; Olin, R.; Mei, M.; Chehrazi-Raffle, A.
Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study

tivozanib联合enivolumab与tivozanib单药治疗在经1或2线含免疫检查点抑制剂（ICI）治疗的肾细胞癌（RCC）患者中的比较：TiNivo-2 III期研究的结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Cerrillo, J. Molina; Garmezy, B.; Barata, P. M. Coelho; McKay, R. R.; Chehrazi-Raffle, A.; Hammers, H.; Heng, D. Y. C.; Braendle, E.; McGregor, B. A.; Albiges, L.
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

卡博替尼和nivolumab联合或不联合活细菌补充治疗转移性肾细胞癌: 一项随机1期试验

NATURE MEDICINE
IF50
2024-06-285
OAAI
Ebrahimi, Hedyeh; Dizman, Nazli; Meza, Luis; Malhotra, Jasnoor; Li, Xiaochen; Dorff, Tanya; Frankel, Paul; Llamas-Quitiquit, Marian; Hsu, Joann; Zengin, Zeynep B.; Alcantara, Marice; Castro, Daniela; Mercier, Benjamin; Chawla, Neal; Chehrazi-Raffle, Alex; Barragan-Carrillo, Regina; Jaime-Casas, Salvador; Govindarajan, Ameish; Gillece, John; Trent, Jeffrey; Lee, Peter P.; Parks, Thomas P.; Takahashi, Motomichi; Hayashi, Atsushi; Kortylewski, Marcin; Caporaso, J. Gregory; Lee, Keehoon; Tripathi, Abhishek; Pal, Sumanta K.
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
NUTRIENTS
IF5
2024-05-260
OAAI
Ebrahimi, Hedyeh; Battle, Dena; Salgia, Nicholas J.; Zengin, Zeynep B.; Dizman, Nazli; Meza, Luis; Bergerot, Cristiane D.; Barragan-Carrillo, Regina; Hsu, JoAnn; Castro, Daniela; Mercier, Benjamin; Chawla, Neal; Li, Xiaochen; Tripathi, Abhishek; Liu, Sandy T.; Chehrazi-Raffle, Alex; Vaishampayan, Ulka; Staehler, Michael D.; Pal, Sumanta K.
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
BJU INTERNATIONAL
IF4.4
2023-09-011
OAAI
Castro, Daniela; Prajapati, Sweta; Feng, Matthew; Chan, Elyse; Lee, Kyle; Paul, Trishita; Sehgal, Ishaan; Patel, Jalen; Li, Xiaochen; Zengin, Zeynep; Ebrahimi, Hedyeh; Govindarajan, Ameish; Meza, Luis; Mercier, Benjamin; Chawla, Neal; Dizman, Nazli; Philip, Errol; Hsu, Joann; Bergerot, Cristiane; Chehrazi-Raffle, Alex; Rock, Adam; Liu, Sandy; Tripathi, Abhishek; Dorff, Tanya; Pal, Sumanta
Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles

通过成像质量细胞术表征乳头状和透明细胞肾细胞癌揭示了不同的免疫学特征

FRONTIERS IN IMMUNOLOGY
IF5.9
2023-08-113
OAAI
Govindarajan, Ameish; Salgia, Nicholas J.; Li, Haiqing; Castro, Daniela V.; Mirzapoiazova, Tamara; Armstrong, Brian; Zhao, Dan; Mercier, Benjamin D.; Dizman, Nazli; Chawla, Neal; Zengin, Zeynep; Meza, Luis; Tripathi, Nishita; Sayegh, Nicolas; Chehrazi-Raffle, Alex; Tripathi, Abhishek; Pal, Sumanta K.
Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma

寡进展性肾细胞癌患者立体定向放射治疗反应的基因组和转录组学预测因子

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2023-08-013
PRE
Zengin, Zeynep B.; Govindarajan, Ameish; Salgia, Nicholas; Sayegh, Nicolas; Tripathi, Nishita; Muddasani, Ramya; Chehrazi-Raffle, Alex; Feng, Matthew; Mercier, Benjamin D.; Ladbury, Colton; Hao, Claire; Salgia, Sabrina; Chawla, Neal; Meza, Luis; Malhotra, Jasnoor; Dizman, Nazli; Hsu, JoAnn; V. Castro, Daniela; Barragan-Carrillo, Regina; Ebrahimi, Hedyeh; Philip, Errol J.; Chang, Mark; Zhang, Jiaming; Byron, Sara; Lyou, Yung; Dorff, Tanya; Pal, Sumanta K.; Dandapani, Savita
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nivolumab联合ipilimumab在转移性肾细胞癌中补充或不补充活细菌: 一项随机1期试验

NATURE MEDICINE
IF50
2022-02-28242
OAAI
Dizman, Nazli; Meza, Luis; Bergerot, Paulo; Alcantara, Marice; Dorff, Tanya; Lyou, Yung; Frankel, Paul; Cui, Yujie; Mira, Valerie; Llamas, Marian; Hsu, Joann; Zengin, Zeynep; Salgia, Nicholas; Salgia, Sabrina; Malhotra, Jasnoor; Chawla, Neal; Chehrazi-Raffle, Alex; Muddasani, Ramya; Gillece, John; Reining, Lauren; Trent, Jeff; Takahashi, Motomichi; Oka, Kentaro; Higashi, Seiya; Kortylewski, Marcin; Highlander, Sarah K.; Pal, Sumanta K.

研究方向

暂未获取到该数据
S
Sumanta K. Pal
H 指数:88论文数:1,402被引数:3.4万
N
Nazlı Dizman
H 指数:24论文数:233被引数:2,617
L
Luís Meza
H 指数:25论文数:215被引数:3,454
J
Joann Hsu
H 指数:20论文数:178被引数:2,030
T
Tanya B. Dorff
H 指数:49论文数:620被引数:1.3万
N
Neal Shiv Chawla
H 指数:12论文数:124被引数:1,177
Z
Zeynep Büşra Zengin
H 指数:14论文数:130被引数:1,100
R
Regina Barragán-Carrillo
H 指数:11论文数:106被引数:515
N
Nicholas Salgia
H 指数:12论文数:85被引数:1,081
D
Daniela V. Castro
H 指数:9论文数:95被引数:301